

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8237791

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	IZUN PHARMACEUTICALS CORPORATION	04/12/2022
RECEIVING PARTY DATA		
Name:	DAY THREE LABS MANUFACTURING INC.	
Street Address:	3215 TEJON STREET, APT 511	
City:	DENVER	
State/Country:	COLORADO	
Postal Code:	80211	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	18490143
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	uspat@jmbdavis.com	
Correspondent Name:	JACQUELINE MIRIAM SHERMAN	
Address Line 1:	P.O. BOX 45087	
Address Line 4:	JERUSALEM, ISRAEL	
ATTORNEY DOCKET NUMBER:	3332/1.3003	
NAME OF SUBMITTER:	JACQUELINE M. SHERMAN	
SIGNATURE:	/Jacqueline M. Sherman/	
DATE SIGNED:	10/24/2023	
Total Attachments: 4		
source=ASSIGNMENT_2#page1.tif		
source=ASSIGNMENT_2#page2.tif		
source=ASSIGNMENT_2#page3.tif		
source=ASSIGNMENT_2#page4.tif		

ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS

This Assignment was made and entered into on the 12 day of April 2022 by and between:

IZUN PHARMACEUTICALS CORPORATION, a Delaware corporation, having a business address at 1 Rockefeller Plaza, 11th Floor, New York, NY 10020, USA ("Assignor"); and

DAY THREE LABS MANUFACTURING INC., a Delaware corporation, having a business address at: 3215 Tejon Street, Apt 511, Denver, CO 80211, USA

("Assignee")

WHEREAS Assignor is the owner of the entire right, title and interest to and in the patents issued and the patent applications pending in various jurisdictions of the world as listed in Schedule A appended hereto (collectively: "the Patents and Patent Applications"; and

WHEREAS Assignor is interested in transferring and assigning to Assignee all of its right, title and interest to and in the Patents and Patent Applications, and Assignee is interested in acquiring from Assignor all of Assignor's right, title and interest to and in the Patents and Patent Applications;

THEREFORE, THE PARTIES HAVE AGREED AS FOLLOWS:

1. For good and valuable consideration, the sufficiency of which is acknowledged, Assignor hereby transfers and assigns to Assignee all of its right, title and interest to and in the Patents and Patent Applications, and Assignee hereby acquires from Assignor all of Assignor's right, title and interest to and in the Patents and Patent Applications.

2. Without derogating from the generality of the above, Assignor hereby declares that the transfer and assignment to the Assignee of its entire right, title and interest to and in the Patents and Patent applications includes the right to claim damages for past infringement of the Patents and any patent that may issue on the Patent Applications, as well as the right, if presently held by Assignor, to claim priority from the first application filed for each of the inventions described and claimed in the Patent Applications.

3. Assignor hereby covenants that it has full right to convey the entire interest herein assigned, and that it has not executed and will not execute any agreement in conflict herewith.

4. Assignor hereby undertakes as follows:

(a) To use its best efforts to ensure that the inventors named on the Patents and Patent Applications will cooperate fully with Assignee, including signing and delivering to Assignee or its representatives any documents needed for the prosecution of the Patents and Patent Applications in the various jurisdictions;

(b) To execute all papers necessary in connection with the Patents and Patent Applications, including continuing or divisional or reissue applications thereof and also to execute separate assignments in connection with any Patent or Patent Application as Assignee may deem necessary or expedient or essential to obtain the grant of patents;

(c) To execute all papers necessary in connection with any legal proceedings in connection with the Patents or Patent Applications (including, without limitation, opposition, post grant review, inter partes proceedings and infringement) and to cooperate with Assignee in every way possible in obtaining evidence and going forward with legal proceedings;



(d) To perform all affirmative acts which may be necessary for Assignee to obtain grants of Letters Patent, provided only that Assignee shall bear all costs related thereto;

(e) To communicate to Assignee or its representatives all relevant facts known to Assignee respecting the inventions described and claimed in the Patents and Patent Applications, and will, upon request, but without expense, testify in any legal proceedings regarding the Patents and Patent Applications;

(f) To authorize and request the competent patent authorities to issue Letters Patent on the Patent Applications to Assignee as Assignee of the entire interest.

5. This Assignment shall be governed by the laws of the State of Delaware.

IN WITNESS WHEREOF THE PARTIES HAVE AFFIXED THEIR SIGNATURES:

ASSIGNOR:  By: Dr. William Z. Levine Title: Chief Scientific Officer	ASSIGNEE:  By: Raphael Cohen Title: Director
--	---

Schedule A

JURISDICTION	APPLICATION/SERIAL NO.	PATENT NO.
Australia	2015232994	2015232994
Australia	2018231789	
Australia	2020339841	
Brazil	11 2019 018638-7	
Brazil	11 2019 019245 0	
Brazil	11 2020008230- 9	
Brazil	11 2022003532 2	
Canada	2,942,867	
Canada	3055692	
Canada	3056556	
Canada	3,079,078	
Canada	3,149,505	
China	201880027907.3	
China	201880030021.4	
China	National Phase of PCT/IL2020/050930	
Colombia	National Phase of PCT/IL2020/050930	
Europe	15764519.3	
Europe	18763376.3	
Europe	18767525.1	3595693
Europe	18870038.9	
Europe	20858013.4	
France	EP 18767525	EP 3595693
Germany	EP 18767525	602018028256.4
India	201627035214	
India	20227010813	
Israel	247881	247881
Israel	269100	
Israel	269305	
Israel	274166	
Israel	290878	
Italy	EP 18767525	EP 3595693
Japan	2019-548645	
Japan	2019-550824	
Mexico	MX/a/2020/004232	
Mexico	MX/a/2022/002372	
PCT	PCT/IB2015/051991	
PCT	PCT/IL2018/050278	
PCT	PCT/IL2018/050307	
PCT	PCT/IL2018/051134	
PCT	PCT/IL2020/050930	
Poland	EP 18767525	EP 3595693
Russia	2020115363	

South Africa	National Phase of PCT/IL2020/050930	
South Korea	10-2016-7028883	
South Korea	10-2019-7029411	
South Korea	10-2019-7029757	
Spain	EP 18767525	EP 3595693
United Kingdom	EP 18767525	EP 3595693
United States of America	61/954,634	
United States of America	62/096,558	
United States of America	14/661,573	10,653,787
United States of America	16/876,143	
United States of America	62/469,022	
United States of America	16/492,142	
United States of America	62/472,329	
United States of America	16/494,320	
United States of America	62/576,685	
United States of America	16/758,857	
United States of America	62/893,201	
United States of America	17/638,827	